Cargando…

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Registries evaluating un-randomized patients have provided valuable information with respect to a therapy’s utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2014
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251407/ https://www.ncbi.nlm.nih.gov/pubmed/25562142 http://dx.doi.org/10.3390/jpm4010052

Ejemplares similares

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
por: Wong, Michael K, et al.
Publicado: (2014)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma
por: Chandar, Ashwin, et al.
Publicado: (2015)

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry
por: Curti, Brendan, et al.
Publicado: (2017)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
por: Alva, Ajjai, et al.
Publicado: (2016)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
por: Dutcher, Janice P, et al.
Publicado: (2014)

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)
por: Clark, Joseph I., et al.
Publicado: (2016)

Establishment of the National Brain Tumor Registry of China
por: Zhang, Liwei, et al.
Publicado: (2020)

Effects of microRNA-146a on the proliferation and apoptosis of human osteochondrocytes by targeting TRAF6 through the NF- κB signalling pathway
por: West, Camilla, et al.
Publicado: (2017)

Global Neurotrauma Surveillance: Are National Databases Overrated?: Comment on "Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries"
por: Boeck, Marissa A., et al.
Publicado: (2022)

Neuroinformatics: From Bioinformatics to Databasing the Brain
por: Morse, Thomas M.
Publicado: (2008)

Multiple Choices: Regulation of Memory CD8 T Cell Generation and Homeostasis by Interleukin (IL)-7 and IL-15
por: Prlic, Martin, et al.
Publicado: (2002)

The Pleiotropic Functions of Interleukin 15: Not so Interleukin 2–Like after All
por: Ma, Averil, et al.
Publicado: (2000)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma
por: Silk, Ann W., et al.
Publicado: (2023)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

The National Gene Vector Biorepository's Pharm/Tox Database
por: Cornetta, Kenneth, et al.
Publicado: (2009)

Heart disease: recruitment of MEF2 activity by β−blockers wards off cardiomyocyte death
por: Hashemi, S, et al.
Publicado: (2015)

Therapeutic Window of Interleukin-2 for Autoimmune Diseases
por: Tang, Qizhi
Publicado: (2015)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

National Trauma Registries in LMICs: Long-Overdue Priority: Comment on "Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries"
por: Asfaw, Zerubabbel K.
Publicado: (2023)

Suspension of the National Registry of Evidence-Based Programs and Practices: the importance of adhering to the evidence
por: Green-Hennessy, Sharon
Publicado: (2018)

Towards creation of national cerebral palsy registries in Arab countries: what is missing?
por: Hassanein, Sahar M. A., et al.
Publicado: (2022)

National Neurotrauma Registry Data in Low- and Middle-Income Countries – Current Status and Future Requirements: Comment on "Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries"
por: Lecky, Fiona
Publicado: (2023)

National Medical School Matching Program: optimizing outcomes
por: Eltorai, Adam EM, et al.
Publicado: (2016)

Neurotrauma Registries in Low- and Middle-Income Countries for Building Organized Neurotrauma Care: The LATINO Registry Experience: Comment on "Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries"
por: Rubiano, Andrés M., et al.
Publicado: (2022)

Utilising Point of Care Diagnostics to Minimise Nosocomial Infection in the 2019 Novel Coronavirus (SARS-CoV-2) Pandemic
por: McDermott, J H, et al.
Publicado: (2020)

What are the Facilitators and Obstacles to Participation in Workplace Team Sport? A Qualitative Study
por: Brinkley, Andrew, et al.
Publicado: (2017)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

CNL and aCML are prognostically distinct: a large National Cancer Database analysis
por: Tremblay, Douglas, et al.
Publicado: (2023)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy
por: Widjaja, Anissa A., et al.
Publicado: (2020)

Leveraging a national cloud-based intensive care registry for COVID-19 surveillance, research and case-mix evaluation in Brazil
por: Quintairos, Amanda, et al.
Publicado: (2022)

The Role of Registries in Neurotrauma Research: Translating Data Into Health Policy That Enhances Patient Care: Comment on "Neurotrauma Surveillance in National Registries of Low- and Middle-Income Countries: A Scoping Review and Comparative Analysis of Data Dictionaries"
por: Thango, Nqobile, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ff089l0jjo008cvs7ou1mmnn95